Preservative Free drop treatment

Phase 3Small molecule

UUniversitaire Ziekenhuizen KU Leuven

Preservative Free drop treatment is one of 52 small molecule programs targeting Cataract. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CataractRecruiting

CataractPhase 3

Recruiting

Competition

Competitive Landscape

63 competitors in Cataract

#DrugCompanyPhaseTrials

Avelox

Bayer

Approved

3 2

Eylea

Regeneron

Approved

3 3

Decadron

AAspen Global Incorporated

Approved

13 4

Bromday

BBausch Health Americas, Inc.

Approved

10 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

9 6

Lovenox

Sanofi

Approved

1 7

Cipro

Voltaren

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 10

Levaquin

WWim Janssens

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cataract1 trial

Comparison of Treatment With Preservative-free Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye Drops After Cataract Surgery

Recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 4·NCT04050644·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Preservative Free drop treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Preservative Free drop treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Preservative Free drop treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universitaire Ziekenhuizen KU Leuven company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversitaire Ziekenhuizen KU Leuven

Preservative Free drop treatment

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cataract1 trial

References

Drug Info

Quick Facts

Related News